{"id":1944,"date":"2025-11-24T14:00:53","date_gmt":"2025-11-24T14:00:53","guid":{"rendered":"https:\/\/www.bioprojet.com\/troubles-centraux-hypersomnolence-1-er-essai-clinique-chez-homme-bp115205\/"},"modified":"2025-11-24T14:14:18","modified_gmt":"2025-11-24T14:14:18","slug":"central-disorders-hypersomnolence-first-human-trial-bp115205","status":"publish","type":"post","link":"https:\/\/www.bioprojet.com\/en\/central-disorders-hypersomnolence-first-human-trial-bp115205\/","title":{"rendered":"Central disorders of hypersomnolence : first human clinical trial on BP1.15205"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":8,"featured_media":1946,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[28],"tags":[],"class_list":["post-1944","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Central Disorders of Hypersomnolence: First Human Clinical Trial on BP1.15205 | Bioprojet | Paris<\/title>\n<meta name=\"description\" content=\"Bioprojet, in partnership with Harmony Biosciences in the United States, announces the launch of the first human clinical trial of BP1.15205, an orexin type 2 receptor agonist, for central disorders of hypersomnolence.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.bioprojet.com\/en\/central-disorders-hypersomnolence-first-human-trial-bp115205\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Central Disorders of Hypersomnolence: First Human Clinical Trial on BP1.15205 | Bioprojet | Paris\" \/>\n<meta property=\"og:description\" content=\"Bioprojet, in partnership with Harmony Biosciences in the United States, announces the launch of the first human clinical trial of BP1.15205, an orexin type 2 receptor agonist, for central disorders of hypersomnolence.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.bioprojet.com\/en\/central-disorders-hypersomnolence-first-human-trial-bp115205\/\" \/>\n<meta property=\"og:site_name\" content=\"Wordpress\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-24T14:00:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-24T14:14:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.bioprojet.com\/app\/uploads\/2025\/11\/central-disorders-hypersomnolence-first-human-trial-bp115205-bioprojet.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2416\" \/>\n\t<meta property=\"og:image:height\" content=\"1366\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Bioprojet NEW\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Bioprojet NEW\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.bioprojet.com\\\/en\\\/central-disorders-hypersomnolence-first-human-trial-bp115205\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.bioprojet.com\\\/en\\\/central-disorders-hypersomnolence-first-human-trial-bp115205\\\/\"},\"author\":{\"name\":\"Bioprojet NEW\",\"@id\":\"https:\\\/\\\/www.bioprojet.com\\\/#\\\/schema\\\/person\\\/85a8f53f87f68fc665e25d38bbf859e6\"},\"headline\":\"Central disorders of hypersomnolence : first human clinical trial on BP1.15205\",\"datePublished\":\"2025-11-24T14:00:53+00:00\",\"dateModified\":\"2025-11-24T14:14:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.bioprojet.com\\\/en\\\/central-disorders-hypersomnolence-first-human-trial-bp115205\\\/\"},\"wordCount\":10,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.bioprojet.com\\\/en\\\/central-disorders-hypersomnolence-first-human-trial-bp115205\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.bioprojet.com\\\/app\\\/uploads\\\/2025\\\/11\\\/central-disorders-hypersomnolence-first-human-trial-bp115205-bioprojet.jpg\",\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.bioprojet.com\\\/en\\\/central-disorders-hypersomnolence-first-human-trial-bp115205\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.bioprojet.com\\\/en\\\/central-disorders-hypersomnolence-first-human-trial-bp115205\\\/\",\"url\":\"https:\\\/\\\/www.bioprojet.com\\\/en\\\/central-disorders-hypersomnolence-first-human-trial-bp115205\\\/\",\"name\":\"Central Disorders of Hypersomnolence: First Human Clinical Trial on BP1.15205 | Bioprojet | Paris\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.bioprojet.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.bioprojet.com\\\/en\\\/central-disorders-hypersomnolence-first-human-trial-bp115205\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.bioprojet.com\\\/en\\\/central-disorders-hypersomnolence-first-human-trial-bp115205\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.bioprojet.com\\\/app\\\/uploads\\\/2025\\\/11\\\/central-disorders-hypersomnolence-first-human-trial-bp115205-bioprojet.jpg\",\"datePublished\":\"2025-11-24T14:00:53+00:00\",\"dateModified\":\"2025-11-24T14:14:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.bioprojet.com\\\/#\\\/schema\\\/person\\\/85a8f53f87f68fc665e25d38bbf859e6\"},\"description\":\"Bioprojet, in partnership with Harmony Biosciences in the United States, announces the launch of the first human clinical trial of BP1.15205, an orexin type 2 receptor agonist, for central disorders of hypersomnolence.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.bioprojet.com\\\/en\\\/central-disorders-hypersomnolence-first-human-trial-bp115205\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.bioprojet.com\\\/en\\\/central-disorders-hypersomnolence-first-human-trial-bp115205\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.bioprojet.com\\\/en\\\/central-disorders-hypersomnolence-first-human-trial-bp115205\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.bioprojet.com\\\/app\\\/uploads\\\/2025\\\/11\\\/central-disorders-hypersomnolence-first-human-trial-bp115205-bioprojet.jpg\",\"contentUrl\":\"https:\\\/\\\/www.bioprojet.com\\\/app\\\/uploads\\\/2025\\\/11\\\/central-disorders-hypersomnolence-first-human-trial-bp115205-bioprojet.jpg\",\"width\":2416,\"height\":1366,\"caption\":\"First human clinical trial on BP1.15205\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.bioprojet.com\\\/en\\\/central-disorders-hypersomnolence-first-human-trial-bp115205\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.bioprojet.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Central disorders of hypersomnolence : first human clinical trial on BP1.15205\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.bioprojet.com\\\/#website\",\"url\":\"https:\\\/\\\/www.bioprojet.com\\\/\",\"name\":\"Wordpress\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.bioprojet.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.bioprojet.com\\\/#\\\/schema\\\/person\\\/85a8f53f87f68fc665e25d38bbf859e6\",\"name\":\"Bioprojet NEW\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ac5df859a50e6dc27ae3cf4303d7f7cfe669f6beb8e81f1eee7870c3a82769e2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ac5df859a50e6dc27ae3cf4303d7f7cfe669f6beb8e81f1eee7870c3a82769e2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ac5df859a50e6dc27ae3cf4303d7f7cfe669f6beb8e81f1eee7870c3a82769e2?s=96&d=mm&r=g\",\"caption\":\"Bioprojet NEW\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Central Disorders of Hypersomnolence: First Human Clinical Trial on BP1.15205 | Bioprojet | Paris","description":"Bioprojet, in partnership with Harmony Biosciences in the United States, announces the launch of the first human clinical trial of BP1.15205, an orexin type 2 receptor agonist, for central disorders of hypersomnolence.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.bioprojet.com\/en\/central-disorders-hypersomnolence-first-human-trial-bp115205\/","og_locale":"en_US","og_type":"article","og_title":"Central Disorders of Hypersomnolence: First Human Clinical Trial on BP1.15205 | Bioprojet | Paris","og_description":"Bioprojet, in partnership with Harmony Biosciences in the United States, announces the launch of the first human clinical trial of BP1.15205, an orexin type 2 receptor agonist, for central disorders of hypersomnolence.","og_url":"https:\/\/www.bioprojet.com\/en\/central-disorders-hypersomnolence-first-human-trial-bp115205\/","og_site_name":"Wordpress","article_published_time":"2025-11-24T14:00:53+00:00","article_modified_time":"2025-11-24T14:14:18+00:00","og_image":[{"width":2416,"height":1366,"url":"https:\/\/www.bioprojet.com\/app\/uploads\/2025\/11\/central-disorders-hypersomnolence-first-human-trial-bp115205-bioprojet.jpg","type":"image\/jpeg"}],"author":"Bioprojet NEW","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Bioprojet NEW","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.bioprojet.com\/en\/central-disorders-hypersomnolence-first-human-trial-bp115205\/#article","isPartOf":{"@id":"https:\/\/www.bioprojet.com\/en\/central-disorders-hypersomnolence-first-human-trial-bp115205\/"},"author":{"name":"Bioprojet NEW","@id":"https:\/\/www.bioprojet.com\/#\/schema\/person\/85a8f53f87f68fc665e25d38bbf859e6"},"headline":"Central disorders of hypersomnolence : first human clinical trial on BP1.15205","datePublished":"2025-11-24T14:00:53+00:00","dateModified":"2025-11-24T14:14:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.bioprojet.com\/en\/central-disorders-hypersomnolence-first-human-trial-bp115205\/"},"wordCount":10,"commentCount":0,"image":{"@id":"https:\/\/www.bioprojet.com\/en\/central-disorders-hypersomnolence-first-human-trial-bp115205\/#primaryimage"},"thumbnailUrl":"https:\/\/www.bioprojet.com\/app\/uploads\/2025\/11\/central-disorders-hypersomnolence-first-human-trial-bp115205-bioprojet.jpg","articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.bioprojet.com\/en\/central-disorders-hypersomnolence-first-human-trial-bp115205\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.bioprojet.com\/en\/central-disorders-hypersomnolence-first-human-trial-bp115205\/","url":"https:\/\/www.bioprojet.com\/en\/central-disorders-hypersomnolence-first-human-trial-bp115205\/","name":"Central Disorders of Hypersomnolence: First Human Clinical Trial on BP1.15205 | Bioprojet | Paris","isPartOf":{"@id":"https:\/\/www.bioprojet.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.bioprojet.com\/en\/central-disorders-hypersomnolence-first-human-trial-bp115205\/#primaryimage"},"image":{"@id":"https:\/\/www.bioprojet.com\/en\/central-disorders-hypersomnolence-first-human-trial-bp115205\/#primaryimage"},"thumbnailUrl":"https:\/\/www.bioprojet.com\/app\/uploads\/2025\/11\/central-disorders-hypersomnolence-first-human-trial-bp115205-bioprojet.jpg","datePublished":"2025-11-24T14:00:53+00:00","dateModified":"2025-11-24T14:14:18+00:00","author":{"@id":"https:\/\/www.bioprojet.com\/#\/schema\/person\/85a8f53f87f68fc665e25d38bbf859e6"},"description":"Bioprojet, in partnership with Harmony Biosciences in the United States, announces the launch of the first human clinical trial of BP1.15205, an orexin type 2 receptor agonist, for central disorders of hypersomnolence.","breadcrumb":{"@id":"https:\/\/www.bioprojet.com\/en\/central-disorders-hypersomnolence-first-human-trial-bp115205\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.bioprojet.com\/en\/central-disorders-hypersomnolence-first-human-trial-bp115205\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.bioprojet.com\/en\/central-disorders-hypersomnolence-first-human-trial-bp115205\/#primaryimage","url":"https:\/\/www.bioprojet.com\/app\/uploads\/2025\/11\/central-disorders-hypersomnolence-first-human-trial-bp115205-bioprojet.jpg","contentUrl":"https:\/\/www.bioprojet.com\/app\/uploads\/2025\/11\/central-disorders-hypersomnolence-first-human-trial-bp115205-bioprojet.jpg","width":2416,"height":1366,"caption":"First human clinical trial on BP1.15205"},{"@type":"BreadcrumbList","@id":"https:\/\/www.bioprojet.com\/en\/central-disorders-hypersomnolence-first-human-trial-bp115205\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.bioprojet.com\/en\/"},{"@type":"ListItem","position":2,"name":"Central disorders of hypersomnolence : first human clinical trial on BP1.15205"}]},{"@type":"WebSite","@id":"https:\/\/www.bioprojet.com\/#website","url":"https:\/\/www.bioprojet.com\/","name":"Wordpress","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.bioprojet.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.bioprojet.com\/#\/schema\/person\/85a8f53f87f68fc665e25d38bbf859e6","name":"Bioprojet NEW","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/ac5df859a50e6dc27ae3cf4303d7f7cfe669f6beb8e81f1eee7870c3a82769e2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ac5df859a50e6dc27ae3cf4303d7f7cfe669f6beb8e81f1eee7870c3a82769e2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ac5df859a50e6dc27ae3cf4303d7f7cfe669f6beb8e81f1eee7870c3a82769e2?s=96&d=mm&r=g","caption":"Bioprojet NEW"}}]}},"_links":{"self":[{"href":"https:\/\/www.bioprojet.com\/en\/wp-json\/wp\/v2\/posts\/1944","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bioprojet.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bioprojet.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bioprojet.com\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bioprojet.com\/en\/wp-json\/wp\/v2\/comments?post=1944"}],"version-history":[{"count":2,"href":"https:\/\/www.bioprojet.com\/en\/wp-json\/wp\/v2\/posts\/1944\/revisions"}],"predecessor-version":[{"id":1949,"href":"https:\/\/www.bioprojet.com\/en\/wp-json\/wp\/v2\/posts\/1944\/revisions\/1949"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bioprojet.com\/en\/wp-json\/wp\/v2\/media\/1946"}],"wp:attachment":[{"href":"https:\/\/www.bioprojet.com\/en\/wp-json\/wp\/v2\/media?parent=1944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bioprojet.com\/en\/wp-json\/wp\/v2\/categories?post=1944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bioprojet.com\/en\/wp-json\/wp\/v2\/tags?post=1944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}